GPT and rheumatoid arthritis: Subgroup analysis indicated that baricitinib 4 mg (net LSM change: 3.59 U/L; 95% CI, 1.75–5.43; P = .0001; I2 = 58%) for the treatment of RA significantly increased the level of ALT compared with the placebo group.